Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Melatonin and Cisplatin Co-Treatment Against Cancer: A Mechanistic Review of Their Synergistic Effects and Melatonin's Protective Actions Publisher Pubmed



Rafiyan M1, 2 ; Davoodvandi A2, 3 ; Reiter RJ4 ; Mansournia MA5 ; Rasooli Manesh SM6 ; Arabshahi V7 ; Asemi Z7
Authors

Source: Pathology Research and Practice Published:2024


Abstract

Combination chemotherapy appears to be a preferable option for some cancer patients, especially when the medications target multiple pathways of oncogenesis; individuals treated with combination treatments may have a better prognosis than those treated with single agent chemotherapy. However, research has revealed that this is not always the case, and that this technique may just enhance toxicity while having little effect on boosting the anticancer effects of the medications. Cisplatin (CDDP) is a chemotherapeutic medicine that is commonly used to treat many forms of cancer. However, it has major adverse effects such as cardiotoxicity, skin necrosis, testicular toxicity, and nephrotoxicity. Many research have been conducted to investigate the effectiveness of melatonin (MLT) as an anticancer medication. MLT operates in a variety of ways, including decreasing cancer cell growth, causing apoptosis, and preventing metastasis. We review the literature on the role of MLT as an adjuvant in CDDP-based chemotherapies and discuss how MLT may enhance CDDP's antitumor effects (e.g., by inducing apoptosis and suppressing metastasis) while protecting other organs from its adverse effects, such as cardio- and nephrotoxicity. © 2023 Elsevier GmbH
Other Related Docs
9. Evidence for the Benefits of Melatonin in Cardiovascular Disease, Frontiers in Cardiovascular Medicine (2022)
14. Cisplatin-Loaded Nanoformulations for Cancer Therapy: A Comprehensive Review, Journal of Drug Delivery Science and Technology (2022)
17. Melatonin for Gastric Cancer Treatment: Where Do We Stand?, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)